Thrilled to see Paradromics’ $20M fund raise lead by the talented Dr. Amy Kruse! Paradromics is building a brain computer interface supported by DARPA’s Biologi… See More.
The investment demonstrates confidence in Paradromics as a well-positioned player in the $200 billion BCI therapy market. Last year, Paradromics successfully completed testing of its platform, demonstrating the largest ever electrical recording of cortical activity that exceeded more than 30000 electrode channels in sheep cortex. This recording allowed researchers to observe the brain activity of sheep in response to sound stimuli with high fidelity.
“We are combining the best of neural science and medical device engineering to create a robust and reliable platform for new clinical therapies,” said Paradromics CEO Matt Angle. “This funding round is a validation of both our technology and strategic vision in leading this important developing market.”
The current funding round follows $10M in early stage private funding as well as $15M of public funding from the National Institutes of Health (NIH) and the Department of Defense (DARPA).
After controlling for factors such as age, sex, handedness, first language, education level, and other variables, the researchers found that those who had contracted COVID-19 tended to underperform on the intelligence test compared to those who had not contracted the virus. The greatest deficits were observed on tasks requiring reasoning, planning and problem solving, which is in line “with reports of long-COVID, where ‘brain fog,’ trouble concentrating and difficulty finding the correct words are common,” the researchers said.
People who have recovered from COVID-19 tend to score significantly lower on an intelligence test compared to those who have not contracted the virus, according to new research published in The Lancet journal EClinicalMedicine. The findings suggest that the SARS-CoV-2 virus that causes COVID-19 can produce substantial reductions in cognitive ability, especially among those with more severe illness.
“By coincidence, the pandemic escalated in the United Kingdom in the middle of when I was collecting cognitive and mental health data at very large scale as part of the BBC2 Horizon collaboration the Great British Intelligence Test,” said lead researcher Adam Hampshire (@HampshireHub), an associate professor in the Computational, Cognitive and Clinical Neuroimaging Laboratory at Imperial College London.
“The test comprised a set of tasks designed to measure different dimensions of cognitive ability that had been designed for application in both citizen science and clinical research. A number of my colleagues contacted me in parallel to point out that this provided an opportunity to gather important data on how the pandemic and COVID-19 illness were affecting mental health and cognition.”
Arm thinks those kinds of applications may not be far away, though. In a paper published last week inNature, researchers from the company detailed a 32-bit microprocessor built directly onto a plastic substrate that promises to be both flexible and dramatically cheaper than today’s chips.
“We envisage that PlasticARM will pioneer the development of low-cost, fully flexible smart integrated systems to enable an ‘internet of everything’ consisting of the integration of more than a trillion inanimate objects over the next decade into the digital world,” they wrote.
Flexible electronics aren’t exactly new, and sensors, batteries, LEDs, antennae, and many other simpler components have all been demonstrated before. But a practical microprocessor that can carry out meaningful computations has been elusive thanks to the large number of transistors required, say the researchers.
More TAME! The first part of this has a lot of result data.
Foresight Biotech & Health Extension Meeting sponsored by 100 Plus Capital. 2021 program & apply to join: https://foresight.org/biotech-health-extension-program/
Nir Barzilai, Albert Einstein School of Medicine. TAME Q&A: Lessons for Progress on Aging.
About Nir Barzilai: Nir Barzilai, MD, is a Professor in the Department of Endocrinology Medicine and the Department of Genetics at the Albert Einstein College of Medicine. He is also the Ingeborg and Ira Leon Rennert Chair of Aging Research at the Albert Einstein College of Medicine. Dr. Barzilai is the founding director of the Institute for Aging Research at Albert Einstein College of Medicine and the Director of the Nathan Shock Center for Excellence in the Basic Biology of Aging, funded by the National Institutes of Health (NIH); the center is coordinating 80 investigators and six program projects on the biology of aging. He is also the director of the Glenn Center of Excellence in the Biology of Human Aging. He is a chaired professor of medicine and of genetics and a member of the Diabetes Research Center and the divisions of endocrinology and geriatrics. Dr. Barzilai’s interests focus on several basic mechanisms in the biology of aging, including the biological effects of nutrients on extending life and the genetic determinants of life span. His team discovered many longevity gene in humans, and they further characterized the phenotype and genotype of humans with exceptional longevity through NIH awards. He also has an NIH Merit award investigating the metabolic decline that accompanies aging and its impact on longevity. Dr. Barzilai has published more than 270 peer-reviewed papers, reviews and chapters in textbooks. Dr. Barzilai serves on several editorial boards and advisory boards of pharmaceutical and start-up companies, and is a reviewer for numerous journals. A Beeson Fellow for Aging Research, Dr. Barzilai has received many other prestigious awards, including the Senior Ellison Foundation Award, the 2010 Irving S. Wright Award of Distinction in Aging Research, the NIA–Nathan Shock Award and a merit award from the NIA for his contributions in elucidating metabolic and genetic mechanisms of aging and was the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) Trial, a multi-center study to prove the concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. He is a founder of CohBar Inc. (now public company) and Medical Advisor for Life Biosciences. He is on the board of AFAR and a founding member of the Academy for Lifespan and Healthspan. He has been featured in major papers, TV programs, and documentaries (TEDx and TEDMED) and has been consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, several International Banks, The Vatican, Pepsico, Milkin Institute, The Economist and Wired Magazine. His book, Age Later: Health Span, Life Span, and the New Science of Longevity, was published by St. Martin’s Press in June of 2020.
Join us: ► Twitter: https://twitter.com/foresightinst. ► Facebook: https://www.facebook.com/foresightinst. ► Instagram: https://www.instagram.com/existentialhope/ ► LinkedIn: https://www.linkedin.com/company/foresight-institute. ► Support to join: https://foresight.org/donate/membership/
Foresight Institute advances technologies for the long-term future of life, focusing on molecular machine nanotechnology, biotechnology, and computer science.
Follow us here for videos concerning our programs on Molecular Machines, Biotechnology & Health Extension, Intelligent Cooperation, and Existential Hope.
Russia has unveiled the Sukhoi Checkmate, a new fifth-generation fighter jet intended to supplement the Su-57 and conquer the international market.
A mockup of the aircraft was presented in a grand ceremony on the opening day of the MAKS airshow in Moscow on July 20, 2021.
“We have been working on the project for just slightly longer than one year. Such a fast development cycle was possible only with the help of advanced computer technologies and virtual testing,” Yuri Slyusar, CEO of United Aircraft Corporation (UAC), said at the event.
AMD’s next-generation Radeon RX 7900 XT GPU featuring the Big Navi 31 RDNA 3 GPU could feature an insane 15360 cores in 60 WGPs.
A brand new rumor regarding AMD’s next-generation and flagship RDNA 3 GPU, the Big Navi 31, which is going to power the Radeon RX 7900 XT graphics card, has been published by Beyond3D forums (via 3DCenter). The rumor suggests that AMD is dropping a very popular GPU terminology from its RDNA 3 lineup.
AMD Radeon RX 7900 XT ‘Big Navi 31’ RDNA 3 GPU To Feature Up To 60 WGPs For A Total of 15360 Cores
We are seeing a lot of rumors regarding AMD’s RDNA 3 GPUs pop up recently. Last we heard, the AMD Big Navi GPU within the RDNA 3 lineup, the Navi 31, was going to feature 240 Compute Units or 120 CUs per die for a total of 15360 cores. But Beyond3D forum member, Bondrewd, is quite confident that the era of the CU or Compute Unit is over and AMD is moving over to WGP or Work Group Processors as the main core block of its next-generation GPUs.
Project offers new step toward study of emergence, ‘materials by design,’ and future nanomagnets.
Using a D-Wave quantum-annealing computer as a testbed, scientists at Los Alamos National Laboratory have shown that it is possible to isolate so-called emergent magnetic monopoles, a class of quasiparticles, creating a new approach to developing “materials by design.”
“We wanted to study emergent magnetic monopoles by exploiting the collective dynamics of qubits,” said Cristiano Nisoli, a lead Los Alamos author of the study. “Magnetic monopoles, as elementary particles with only one magnetic pole, have been hypothesized by many, and famously by Dirac, but have proved elusive so far.”
